• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Aprea Therapeutics Inc.

    4/30/26 6:40:04 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APRE alert in real time by email
    DEFA14A 1 apre-20260430xdefa14a.htm DEFA14A

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    (Amendment No. ___)

    ☒ Filed by the Registrant                          ☐ Filed by a party other than the Registrant

    ​

    Check the appropriate box:

    ☐   Preliminary Proxy Statement

    ☐   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐   Definitive Proxy Statement

    ☒   Definitive Additional Materials

    ☐   Soliciting Material under §240.14a-12

    ​

    Aprea Therapeutics, Inc.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    ​

    Payment of Filing Fee (Check the appropriate box):

    ☒   No fee required.

    ☐   Fee paid previously with preliminary materials.

    ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

    ​

    ​

    ​

    ​

    .


    GRAPHIC

    Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V94880-P50669 APREA THERAPEUTICS, INC. 3805 OLD EASTON ROAD DOYLESTOWN, PA 18902 APREA THERAPEUTICS, INC. 2026 Annual Meeting Vote by June 15, 2026 11:59 PM ET You invested in APREA THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 16, 2026. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 2, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote Virtually at the Meeting* June 16, 2026 9:00 A.M. Eastern Time Virtually at: www.virtualshareholdermeeting.com/APRE2026 *Please check the meeting materials for any special requirements for meeting attendance.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V94881-P50669 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. ELECTION OF THREE CLASS I DIRECTORS 01) Marc Duey For 02) Richard Peters, M.D. 03) Bernd R. Seizinger, M.D., Ph.D. 2. To ratify the appointment of EisnerAmper LLP as our independent registered public accounting firm for fiscal year 2026. For 3. To approve an amendment to the Amended and Restated Certificate of Incorporation and to authorize the Board of Directors to effect a reverse stock split of common stock at a ratio of not less than one-for-three and not more than one-for-eight of the common stock (with all fractional shares rounded up to the nearest whole share) (the “Reverse Stock Split”), with the exact ratio to be set within this range by the Board of Directors in its sole discretion (without reducing the authorized number of shares of the common stock), and with the Reverse Stock Split to be effected at such time and date, if at all, as determined by the Board of Directors in its sole discretion. For 4. To approve, by non-binding advisory vote, the compensation of our named executive officers. For 5. To approve, by non-binding advisory vote, the frequency of future votes on the compensation of our named executive officers. 1 Year 6. To approve the adjournment of the annual meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3. For

    Get the next $APRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APRE

    DatePrice TargetRatingAnalyst
    8/20/2021Neutral → Underweight
    JP Morgan
    8/16/2021Buy → Hold
    Berenberg
    8/16/2021$6.00 → $4.00Neutral
    HC Wainwright & Co.
    8/13/2021$6.00 → $5.00Sector Perform
    RBC Capital
    8/13/2021$5.00 → $3.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $APRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President/CEO Gilad Oren bought $25,009 worth of shares (28,100 units at $0.89), increasing direct ownership by 8% to 373,720 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:08:08 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. bought $5,073 worth of shares (5,700 units at $0.89), increasing direct ownership by 21% to 33,433 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:05:34 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Duey Marc bought $25,000 worth of shares (21,459 units at $1.17), increasing direct ownership by 9% to 256,155 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    12/11/25 8:31:55 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

    Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor typesManageable tolerability confirmed across cohortsPatient expansion into uterine serous carcinoma and platinum-resistant ovarian cancer underway; dose escalation and backfill expansion expected to complete Q2 2027 DOYLESTOWN, Pa., June 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, announces the presentation of a poster "Early results

    6/1/26 8:00:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

    Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose escalation ACESOT-1051 trial of WEE1 inhibitor APR-1051Additional clinical data from ACESOT-1051 to be provided at the ASCO 2026 Annual Meeting on May 30, 2026$46.5 million in cash and cash equivalents as of March 31, 2026, with anticipated cash runway into Q1 2028 DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of

    5/13/26 6:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors

    CatalYm today announced the appointment of seasoned biotech executive Christian S. Schade as Chairman of the Board of Directors. With over 30 years of executive leadership experience across private and public biopharma companies, Mr. Schade will provide board leadership at a crucial stage for the company, following the initiation of four late-stage clinical studies of its lead candidate, the GDF-15 inhibitor visugromab. "With recent positive clinical data, multiple ongoing clinical studies, and a strong leadership team with deep biotechnology and drug development expertise, CatalYm is well positioned for continued clinical and corporate success," said Christian S. Schade, Chairman of the

    4/28/26 7:00:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Hamill John P.

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    4/1/26 4:15:55 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Peters Richard

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    4/1/26 4:15:17 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President/CEO Gilad Oren was granted 20,175 shares, increasing direct ownership by 5% to 393,895 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    3/16/26 6:07:28 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aprea Therapeutics downgraded by JP Morgan

    JP Morgan downgraded Aprea Therapeutics from Neutral to Underweight

    8/20/21 5:10:20 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics downgraded by Berenberg

    Berenberg downgraded Aprea Therapeutics from Buy to Hold

    8/16/21 7:29:48 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Aprea Therapeutics with a new price target

    HC Wainwright & Co. reiterated coverage of Aprea Therapeutics with a rating of Neutral and set a new price target of $4.00 from $6.00 previously

    8/16/21 6:35:21 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Aprea Therapeutics Inc.

    SCHEDULE 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)

    5/15/26 5:00:52 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B7 filed by Aprea Therapeutics Inc.

    424B7 - Aprea Therapeutics, Inc. (0001781983) (Filer)

    5/15/26 4:30:26 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Aprea Therapeutics Inc.

    10-Q - Aprea Therapeutics, Inc. (0001781983) (Filer)

    5/13/26 6:46:09 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Leadership Updates

    Live Leadership Updates

    View All

    CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors

    CatalYm today announced the appointment of seasoned biotech executive Christian S. Schade as Chairman of the Board of Directors. With over 30 years of executive leadership experience across private and public biopharma companies, Mr. Schade will provide board leadership at a crucial stage for the company, following the initiation of four late-stage clinical studies of its lead candidate, the GDF-15 inhibitor visugromab. "With recent positive clinical data, multiple ongoing clinical studies, and a strong leadership team with deep biotechnology and drug development expertise, CatalYm is well positioned for continued clinical and corporate success," said Christian S. Schade, Chairman of the

    4/28/26 7:00:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Frazier Life Sciences Appoints Christian Schade as Senior Advisor

    Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Christian Schade as Senior Advisor. Chris will join FLS' Boston office and work closely with the firm's portfolio companies on corporate strategy and business development. "Chris brings deep operational and financial experience with both private and public biopharma companies," said Joe Cabral, Partner at Frazier Life Sciences. "His leadership experience and ability to guide companies through critical inflection points make him a strong addition to our advisory team. We're pleased to welcome him as we continue building out our Boston team." Mr. Schade joins

    4/6/26 8:00:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

    Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutationClinical team strengthened with the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor to support next phase of clinical developmentCapital is in place to support key milestones, including additional enrollment of patients at key dose levels in ongoing ACESOT-1051 trial DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targe

    3/16/26 8:00:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Financials

    Live finance-specific insights

    View All

    Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

    BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "This is an exciting time for Aprea as we advance our ATR program into clinical development this year, continue to progress our WEE1 program toward IND submission and leverage our unique discovery platform capabilities to build for future success," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "We believe o

    8/11/22 4:15:00 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

    BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. ("Atrin") and reported financial results for the three months ended March 31, 2022. Business Operations Update:  On May 16, 2022 Aprea completed the acquisition of Atrin, a privately held biotechnology company focused on the discovery and development of novel therapeutics targeting proteins in the DNA damage response, or DDR, pathway in oncology through synthetic lethality. The Company believes its cash and cash

    5/16/22 9:21:33 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

    BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its clinical trials of eprenetapopt in combination with azacitidine in its myeloid malignancy programs. The partial clinical hold does not apply to the Company's ongoing clinical trials in lymphoid malignancies and solid tumors, or the APR-548 clinical trial. There are approximately 20 patients currently receiving eprenetapopt in combination with azacitidine i

    8/5/21 5:00:00 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Aprea Therapeutics Inc.

    SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)

    10/10/24 4:07:13 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aprea Therapeutics Inc.

    SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)

    2/14/24 8:00:11 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Aprea Therapeutics Inc. (Amendment)

    SC 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

    2/7/24 6:55:18 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care